{"nctId":"NCT02260817","briefTitle":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer","startDateStruct":{"date":"2014-10","type":"ACTUAL"},"conditions":["Metastatic Prostate Cancer"],"count":109,"armGroups":[{"label":"Expanded Access for 11C-Choline","type":"EXPERIMENTAL","interventionNames":["Drug: 11C-choline Injection"]},{"label":"11C-Choline Comparison of Modalities","type":"EXPERIMENTAL","interventionNames":["Drug: 11C-choline Injection"]}],"interventions":[{"name":"11C-choline Injection","otherNames":["CCH Injection, C11 Choline Injection"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. For biochemical relapse after primary treatment\n\n   1. PSA \\> 0.2 ng/ml after radical prostatectomy confirmed at that level or higher on a subsequent test 3 months later\n   2. PSA increase \\>2 ng/ml from nadir following radiation therapy\n   3. PSA increase \\>2 ng/ml from nadir following radiation therapy plus androgen deprivation therapy with nadir defined with normalized testosterone level\n   4. Two consecutive PSA increases from nadir level after androgen blockade or androgen suppression therapy\n2. Kidney function with GFR \\> 60 mL/sec/1.73m2 and Creatinine \\< 1.7mg, collected within 90 days of planned scan\n\n   1. if GFR is \\> or equal to 60 mL/sec/1.73m2, PET/CT will be completed with contrast\n   2. if GFR is \\< 60 mL/sec/1.73m2, PET/CT will be completed without contrast\n   3. if Creatinine is \\> than 1.7 mg, Radiology will follow ACR recommendations as outlined in department policy.\n3. No known allergy to iodinated radiologic contrast media\n4. Able to have MRI based on screening evaluation. If patient is found to be MRI incompatible, the 11C-choline PET/MRI portion of the study will not be completed. Please see the provided contact numbers for further options.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n\nExclusion Criteria:\n\n1. ECOG Performance Status \\> 2.\n2. Concurrent malignancy, i.e. colon cancer.\n3. Treatment for another malignancy except superficial skin cancer within 5 years","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evidence of Metastatic Prostate Cancer","description":"The CT and MRI images will be evaluated for evidence of metastatic prostate cancer. This Outcome is only measured for Arm 2 of this study.\n\nTrue Positive: True positives will consist of evidence of metastatic prostate cancer on conventional CT or MRI images or on 11C-choline PET/CT or MRI images confirmed with biopsy, surgical pathology, or by response to treatment with androgen suppression or other medical or radiation therapy.\n\nTrue Negative: True negatives will consist of negative images.\n\nFalse Positive: False positive will consist of evidence of metastatic prostate cancer on conventional CT or MRI images or on 11C-choline PET/CT or MRI images, but without corresponding confirmation from biopsy, surgical pathology or response to treatment.\n\nFalse Negative: False negative will consist of negative images, but with positive biopsy, surgical pathology or a response to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Sensitivity of 11C Choline PET Imaging Scans","description":"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for imaging sensitivity.\n\nSensitivity of 11C-choline PET/CT and MRI will be calculated as True Positive / (True Positive + False Negative).\n\nThis Outcome is only measured for Arm 2 of this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"97.29","spread":null}]}]}]},{"type":"PRIMARY","title":"Specificity of 11C Choline PET Imaging Scans","description":"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for imaging specificity.\n\nSpecificity of 11C-choline PET/CT and MRI will be calculated as True Negative / (True Negative + False Positive).\n\nThis Outcome is only measured and reported for Arm 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"47.61","spread":null}]}]}]},{"type":"PRIMARY","title":"Positive Predictive Value (PPV) of 11C Choline PET Imaging Scans","description":"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for the images' positive predictive value.\n\nPositive Predictive Value of 11C-choline PET/CT and MRI will be calculated as True Positive / (True Positive + False Positive).\n\nThis Outcome is only measured for Arm 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"76.59","spread":null}]}]}]},{"type":"PRIMARY","title":"Negative Predictive Value (NPV) of 11C Choline PET Imaging Scans","description":"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for the images' negative predictive value.\n\nNegative Predictive Value of 11C-choline PET/CT and MRI will be calculated as True Negative / (True Negative + False Negative).\n\nThis Outcome is only measured for Arm 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"90.90","spread":null}]}]}]},{"type":"PRIMARY","title":"Count of Participants With Positive or Negative PET, CT, or MRI Modalities Resulting in Prostate Cancer (PCa) Confirmation","description":"Comparison of the results of participants' imaging modalities and whether those imaging modalities resulted in confirmation of Prostate Cancer (PCa). This Outcome is only measured for Arm 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Age at Primary Treatment","description":"The median age at primary treatment for Arm 2 participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Median PSA at Diagnosis of Arm 2 Participants","description":"The Prostate-Specific Antigen (PSA) measurement of participants at their original prostate cancer diagnosis was collected at entry to this trial. It is reported as nanograms of PSA per milliliter (ng/mL) of blood. The Median of all reported PSAs is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"13.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical T (cT) Stage of Arm 2 Participants","description":"An accounting of the approximate clinical (pre-treatment) stage for the Arm 2 participants. Clinical staging is based on the results of tests done before surgery.\n\nT1: PC is too small to be seen on a scan or felt during prostate examination\n\nT1a: PC is in \\< 5% of removed tissue\n\nT1b: PC is in \\> 5% or more of removed tissue\n\nT1c: PC is found by biopsy\n\nT2: PC is completely inside prostate\n\nT2a: PC is in only half of one side of prostate\n\nT2b: PC is in more than half of one side of prostate, but not both sides\n\nT2c: PC is in both sides but is still inside prostate\n\nT3: PC has broken through the capsule of prostate\n\nT3a: PC has broken through the capsule of prostate\n\nT3b: PC has spread into seminal vesicles\n\nT4: PC has spread into other nearby body organs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Primary Biopsy Gleason Score of Arm 2 Participants","description":"The median primary Biopsy Gleason Score for the Arm 2 participants' will be reported.\n\nThe Gleason Score is the grading system used to determine the aggressiveness of prostate cancer. Typical Gleason Scores range from 6-10. The higher the Gleason Score, the more likely that the cancer will grow and spread quickly.\n\nGleason scores 2-4 are typically found in smaller tumors located in the transitional zone (around the urethra).\n\nThe majority of treatable/treated cancers are of Gleason scores 5 - 7 and are detected due to biopsy after abnormal digital rectal exam or prostate specific antigen evaluation. The cancer is typically located in the peripheral zone usually the posterior portion.\n\nTumors with Gleason scores 8-10 tend to be advanced neoplasms that are unlikely to be cured.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Treatment Modality of Arm 2 Participants","description":"An accounting of the primary treatment modalities undergone by the participants in Arm 2 prior to their involvement in the trial will be reported.\n\nModalities reported below are:\n\nAndrogen Deprivation Therapy (ADT) External Beam Radiation Therapy (EBRT) Brachytherapy Cryoablation Cystoprostatectomy Intensity-Modulated Radiation Therapy (IMRT) Radical Prostatectomy (RP)","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Pathological Stage (pT) of Prostate Cancer (PC) of Arm 2 Participants","description":"The pathological stage of PC at primary diagnosis for Arm 2 participants was collected. pT is based on how different from normal the cells in samples of tissue recovered from surgery look under a microscope.\n\nT1: PC is too small to be seen on a scan or felt during prostate examination\n\nT1a: PC is in \\< 5% of removed tissue\n\nT1b: PC is in \\> 5% or more of removed tissue\n\nT1c: PC is found by biopsy\n\nT2: PC is completely inside prostate\n\nT2a: PC is in only half of one side of prostate\n\nT2b: PC is in more than half of one side of prostate, but not both sides\n\nT2c: PC is in both sides but is still inside prostate\n\nT3: PC has broken through the capsule of prostate\n\nT3a: PC has broken through the capsule of prostate\n\nT3b: PC has spread into seminal vesicles\n\nT4: PC has spread into other nearby body organs","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Surgical Margins of Arm 2 Participants","description":"A census of the primary surgical margins of participants in Arm 2 will reported.\n\nThe surgical margins are the set of surfaces that were cut by the surgeon in order to remove the specimen from the body.\n\nPositive Margin: surgical margins with disease present. Negative Margin: surgical margins with no disease present.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Positive Lymph Node Ratio of Arm 2 Participants","description":"A census of the positive lymph node ratio, defined as ratio of positive lymph nodes to all lymph nodes removed, for the participants of Arm 2 will be reported.\n\nThe N refers to the the number of nearby lymph nodes that have cancer. NX: Cancer in nearby lymph nodes cannot be measured. N0: There is no cancer in nearby lymph nodes. N1, N2, N3: Refers to the number and location of lymph nodes that contain cancer. The higher the number after the N, the more lymph nodes that contain cancer.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Additional Treatment and Type for Arm 2 Participants","description":"A census of the additional treatments undergone by participants prior to enrollment in the study, if undergone, for the participants of Arm 2 will be reported.\n\nNone Androgen Deprivation Therapy (ADT) Radiation Therapy (RT) Electron Beam Radiation Therapy (EBRT) Lycopene (herbal treatment) Salvage Radiation Therapy (RT) Salvage Radical Prostatectomy (RP) Adjuvant Radiation Therapy (RT) Bilateral Pelvis Lymph Node Dissection","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Months to Biochemical Relapse of Arm 2 Participants","description":"The median of the Arm 2 participants' data between initial treatment and biochemical relapse, occurring prior to study enrollment, measured in months, will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Age of Arm 2 Participant at PET Imaging","description":"The median age (at time of study) of participants of Arm 2 will be reported in years.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Median PSA of Arm 2 Participant at PET Imaging","description":"The median of the PSA of Arm 2 participants at study entry will be reported as nanograms of PSA per milliliter (ng/mL) of blood","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Median PSA Doubling Time of Arm 2 Participants at PET Imaging","description":"The median of the time, measured in months that an Arm 2 participant's PSA has doubled from initial diagnosis to PSA measured at study enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"4.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Median PSA Velocity of Arm 2 Participants at PET Imaging","description":"The median PSA velocity (measured in ng/mL/month) of the Arm 2 participants will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"ADT (Androgen Deprivation Therapy) in Participant at PET Imaging","description":"An accounting of whether the participants of Arm 2 have undergone androgen deprivation therapy (ADT).","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"48","spread":null}]},{"measurements":[{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":[]}}}